Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Cue Biopharma ( (CUE) ).
On March 10, 2025, Cue Biopharma, a company in the biopharmaceutical industry, appointed Pasha Sarraf to its board of directors. This appointment follows the recommendation of the Corporate Governance and Nominating Committee. Mr. Sarraf’s appointment does not involve any arrangements or transactions that require disclosure under regulatory guidelines. He will receive compensation according to the company’s Director Compensation Policy, including an option to purchase 48,800 shares of the company’s common stock, which will vest over three years. Additionally, Mr. Sarraf entered into an indemnification agreement with the company, which may require Cue Biopharma to cover certain expenses related to his service as a director.
More about Cue Biopharma
YTD Price Performance: -4.59%
Average Trading Volume: 292,863
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $65.88M
For an in-depth examination of CUE stock, go to TipRanks’ Stock Analysis page.